Comparative Pharmacology
Head-to-head clinical analysis: TRIPROLIDINE AND PSEUDOEPHEDRINE versus ZYRTEC D 12 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIPROLIDINE AND PSEUDOEPHEDRINE versus ZYRTEC D 12 HOUR.
TRIPROLIDINE AND PSEUDOEPHEDRINE vs ZYRTEC-D 12 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triprolidine is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing histamine-mediated allergic symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and decreased nasal congestion.
Cetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the respiratory tract mucosa, causing vasoconstriction and reduced edema.
1 tablet (2.5 mg triprolidine/60 mg pseudoephedrine) orally every 4-6 hours; max 4 tablets/24 hours.
1 tablet (5 mg cetirizine / 120 mg pseudoephedrine) orally every 12 hours. Maximum 2 tablets per 24 hours.
None Documented
None Documented
Triprolidine: 2-4 hours (parent compound). Pseudoephedrine: 4-8 hours, prolonged in alkaline urine (up to 16-24 hours).
Cetirizine: 8-10 hours in healthy adults; increased in renal impairment (e.g., up to 30 hours in severe impairment). Pseudoephedrine: 5-8 hours (pH-dependent; longer in alkaline urine).
Triprolidine: renal, 70% unchanged and metabolites. Pseudoephedrine: renal, 90% unchanged.
Cetirizine: 70% renal (unchanged), 10% fecal. Pseudoephedrine: 90% renal (unchanged), remainder metabolized and excreted in urine.
Category A/B
Category C
Antihistamine
Antihistamine and Decongestant Combination